Monkeypox virus binding protein and its application, monkeypox virus detection kit

By combining monkeypox virus binding proteins with markers and utilizing antigen-antibody reactions, monkeypox virus detection test strips and kits have been developed, solving the problems of rapid, accurate, and safe monkeypox virus detection, and are suitable for pandemic detection of monkeypox virus.

CN116041489BActive Publication Date: 2026-11-17DYNAMIKER BIOTECH TIANJIN +2
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202211188887.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-09-27
Publication Date
2026-11-17
Estimated Expiration
2042-09-27

AI Technical Summary

Technical Problem

Existing technologies for monkeypox virus detection involve cumbersome procedures and long testing cycles, making it difficult to quickly, accurately, and safely detect a large number of suspected cases, asymptomatic infections in the incubation period, and asymptomatic virus carriers, thus failing to effectively contain the pandemic.

Method used

We provide monkeypox virus binding protein and its test strips and kits. The monkeypox virus binding protein reacts with markers (such as colloidal gold, colored microspheres, time-resolved fluorescent microspheres, or quantum dot microspheres) to form an antigen-antibody reaction, enabling rapid and convenient detection.

Benefits of technology

It enables rapid, accurate, and safe monkeypox virus detection, is suitable for rapid on-site testing, reduces potential infection risks, is applicable to suspected cases and asymptomatic virus carriers, and simplifies the testing process.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN116041489B_ABST
    Figure CN116041489B_ABST
Patent Text Reader

Abstract

This invention provides a monkeypox virus binding protein and its applications, as well as a monkeypox virus detection kit, belonging to the field of biotechnology. The monkeypox virus binding protein provided by this invention is selected from proteins a, b, c, d, e, or f, and the amino acid sequences of the heavy chain complementarity-determining regions and light chain complementarity-determining regions of the binding protein are defined. This monkeypox virus binding protein exhibits high specificity, high biological activity, strong stability, and high affinity for monkeypox virus, and can be used to prepare products for detecting monkeypox virus. The monkeypox virus detection kit provided by this invention has the advantages of simple operation, rapid reaction, high sensitivity, strong specificity, suitability for rapid on-site detection, and cost-effectiveness. It can be used for rapid screening during viral pandemics, enabling rapid, accurate, and safe timely detection of large populations, including suspected cases, asymptomatic infections in the incubation period, and higher-risk asymptomatic virus carriers.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biotechnology, and in particular to monkeypox virus binding proteins and their applications, as well as monkeypox virus detection kits. Background Technology

[0002] Early and accurate diagnosis of infectious diseases is the foundation for timely isolation and effective treatment, effectively preventing their spread. Infectious disease testing includes the isolation and culture of pathogenic microorganisms, the detection of pathogenic microorganism antigens, and the nucleic acid testing of pathogenic microorganisms. Among these, the isolation and culture of pathogenic microorganisms and viruses is a crucial method for infectious disease detection. The results of isolation and culture, revealing the mutations of the causative bacteria or viruses and predicting the trend of infectious diseases, are of great significance. The development of molecular biology techniques has led to the widespread adoption of nucleic acid testing. This is based on the fact that every organism has a specific nucleic acid and DNA sequence. Detecting the gene sequence of a specific virus or pathogenic microorganism in the human body proves infection. The strength of the detected signal determines the degree of infection. This method has the advantages of high sensitivity and specificity, but requires professional operators. Pathogen antigen testing is an important serological detection method. It has no special requirements for laboratories and offers the advantages of early screening and early diagnosis, making it suitable for large-scale screening in grassroots communities.

[0003] Monkeypox, also known as monkeypox, is a zoonotic disease caused by the monkeypox virus (MPXV). It can be transmitted through close contact and through contact with contaminated materials, and can spread between humans and between humans and animals. Currently, the virus is spreading globally across geographical boundaries of natural foci, becoming the most serious orthopox virus-related disease since the eradication of smallpox. The number of confirmed cases is enormous and growing exponentially. There are currently no clinically validated effective drugs against monkeypox; therefore, early diagnosis is crucial to effectively curb its spread.

[0004] Laboratory tests for monkeypox infection include general examinations and etiological examinations. Etiological examinations are mainly conducted through virus culture and nucleic acid testing. Virus culture needs to be carried out in a biosafety level 3 or higher laboratory. Nucleic acid testing is mainly conducted by identifying and detecting rashes, vesicle fluid, scabs, and oropharyngeal and nasal secretions through nucleic acid amplification.

[0005] The above methods have the problems of cumbersome testing steps and long testing cycles, which are not conducive to rapid screening during a viral pandemic. They cannot quickly, accurately and safely test a large number of people, including suspected cases, asymptomatic infected cases in the incubation period and asymptomatic virus carriers at higher risk.

[0006] In view of this, the present invention is hereby proposed. Summary of the Invention

[0007] The primary objective of this invention is to provide a monkeypox virus binding protein that can specifically recognize monkeypox virus.

[0008] A second objective of this invention is to provide the application of the above-mentioned monkeypox virus binding protein in the preparation of monkeypox virus detection products.

[0009] A third objective of the present invention is to provide a monkeypox virus detection test kit to solve at least one of the above-mentioned problems.

[0010] In a first aspect, the present invention provides a monkeypox virus binding protein selected from protein a, protein b, protein c, protein d, protein e, or protein f;

[0011] The protein a includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, as shown in SEQ ID NO.1-3, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, as shown in SEQ ID NO.4-6.

[0012] The protein b includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, with amino acid sequences as shown in SEQ ID NO.7-9, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, with amino acid sequences as shown in SEQ ID NO.10-12.

[0013] The protein c includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, with amino acid sequences as shown in SEQ ID NO.13-15, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, with amino acid sequences as shown in SEQ ID NO.16-18.

[0014] The protein d includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, with amino acid sequences as shown in SEQ ID NO.19-21, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, with amino acid sequences as shown in SEQ ID NO.22-24.

[0015] The protein e includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, as shown in SEQ ID NO. 25-27, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, as shown in SEQ ID NO. 28-30.

[0016] The protein f includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, with amino acid sequences as shown in SEQ ID NO. 31-33, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, with amino acid sequences as shown in SEQ ID NO. 34-36.

[0017] As a further technical solution, the protein a includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO.37-38 in sequence;

[0018] The protein b includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO.39-40, respectively.

[0019] The protein c includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO.41-42;

[0020] The protein d includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO.43-44;

[0021] The protein e includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO.45-46, respectively.

[0022] The protein f includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO.47-48;

[0023] Preferably, the monkeypox virus binding protein is of rabbit origin.

[0024] Secondly, the present invention provides the application of the monkeypox virus binding protein in the preparation of monkeypox virus detection products.

[0025] Thirdly, the present invention provides a monkeypox virus detection test strip, the test strip comprising a base plate and a sample loading pad, a marking pad, a detection pad and a sample absorption pad sequentially stacked on the base plate;

[0026] The labeling pad contains the monkeypox virus binding protein, which is labeled with a marker.

[0027] As a further technical solution, the marker includes at least one of colloidal gold, colored microspheres, time-resolved fluorescent microspheres, or quantum dot microspheres;

[0028] Preferably, the particle size of colloidal gold is 40–100 nm;

[0029] Preferably, the particle sizes of the colored microspheres, time-resolved fluorescent microspheres, and quantum dot microspheres are each independently 100–300 nm;

[0030] Preferably, the mass ratio of monkeypox virus conjugate protein to colloidal gold is (0.04-0.32):1; the mass ratio of monkeypox virus conjugate protein to colored microspheres, time-resolved fluorescent microspheres or quantum dot microspheres is (0.1-0.4):1.

[0031] As a further technical solution, the detection pad is provided with detection lines and quality control lines;

[0032] The detection line is coated with 1–2 mg / ml of the monkeypox virus binding protein described above;

[0033] The quality control line is coated with 1–2 mg / ml of sheep-derived IgG polyclonal antibody;

[0034] Preferably, the diluent for monkeypox virus binding protein and sheep-derived IgG polyclonal antibody is a 15-25 mM PB buffer containing trehalose, with each 100 ml of diluent containing 0.1-0.9 g of trehalose.

[0035] As a further technical solution, the monkeypox virus binding protein on the labeling pad is different from the monkeypox virus binding protein on the detection pad.

[0036] Fourthly, the present invention provides a monkeypox virus detection kit, comprising the monkeypox virus detection test strip and a housing, wherein the monkeypox virus detection test strip is disposed inside the housing.

[0037] As a further technical solution, the housing includes a detachably connected upper cover and a lower cover;

[0038] The top cover is equipped with an observation window and a sample application hole.

[0039] As a further technical solution, the test samples of the monkeypox virus detection kit include at least one of blood, saliva, pus from the infected site, or scabs.

[0040] Preferably, the monkeypox virus detection kit further includes a sample extraction solution;

[0041] The blood sample extraction solution is 45-55 mM PB buffer, and each 100 mL of 45-55 mM PB buffer contains 0.4 g-0.6 g Tritonx-100, 0.1-0.3 g Proclin 300, 0.4 g-0.6 g sodium caseinate, and 0.8 g-1 g NaCl;

[0042] The extraction solution for saliva samples and pustules from infected sites was 90–110 μm Tris buffer. Each 100 mL of 90–110 μm Tris buffer contained 0.9 g NaCl, 0.4–0.6 g Tritonx-100, and 0.4–0.6 g Tween 20. The pH of the extraction solution was 8.5.

[0043] Compared with the prior art, the present invention has the following beneficial effects:

[0044] The monkeypox virus binding protein provided by this invention has good specificity, high biological activity, strong stability, and high affinity for monkeypox virus, and can be used to prepare products for detecting monkeypox virus.

[0045] The monkeypox virus detection kit provided by this invention has the advantages of simple operation, rapid response, high sensitivity, strong specificity, suitability for rapid on-site detection, and cost-effectiveness. It can be used for rapid screening during a viral pandemic, enabling timely, accurate, and safe detection of a large number of people, including suspected cases, asymptomatic infected cases in the incubation period, and asymptomatic virus carriers at higher risk. This indirectly aims to address the insufficient capacity for monkeypox nucleic acid detection and reduce potential transmission risks. Attached Figure Description

[0046] To more clearly illustrate the specific embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the specific embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained from these drawings without creative effort.

[0047] Figure 1 This is the top cover of the monkeypox virus detection kit of the present invention;

[0048] Figure 2 This is the lower cap of the monkeypox virus detection kit of the present invention;

[0049] Figure 3 This is a structural diagram of the monkeypox virus detection test strip of the present invention;

[0050] Figure 4 Electrophoresis image of anti-monkeypox virus monoclonal antibody;

[0051] Figure 5 The image shows the test results.

[0052] Icons: 1-Observation window; 2-Sample loading hole; 3-Test card loading area; 4-Base plate; 5-Test pad; 6-Sample suction pad; 7-Marker pad; 8-Sample loading pad; 9-Control line; 10-Test line. Detailed Implementation

[0053] The embodiments and examples of the present invention will be described in detail below. However, those skilled in the art will understand that the following embodiments and examples are for illustrative purposes only and should not be considered as limiting the scope of the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention. Unless otherwise specified, conventional conditions or conditions recommended by the manufacturer shall apply. Reagents or instruments whose manufacturers are not specified are all commercially available conventional products.

[0054] It should be noted that the "variable region" or "variable domain" of an antibody refers to the amino-terminal domain of either the heavy or light chain. The variable domain of the heavy chain can be referred to as "VH," and the variable domain of the light chain as "VL." These domains are typically the most variable parts of the antibody and contain antigen-binding sites. The variable region of the light or heavy chain consists of a framework region interrupted by three hypervariable regions called "complementarity-determining regions" or "CDRs." The framework region of the antibody, that is, the framework region of the combination of the light and heavy chains, plays a role in locating and aligning the CDRs, which are primarily responsible for binding to the antigen.

[0055] The “framework” or “FR” region refers to the region outside of those defined as CDRs of the antibody variable domain. Each antibody variable domain framework can be further subdivided into adjacent regions separated by CDRs (FR1, FR2, FR3, and FR4).

[0056] Typically, the variable regions VL / VH of heavy and light chains can be obtained by connecting the following numbered CDRs with FRs in the following combination: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.

[0057] In this invention, CDR1-VH, CDR2-VH and CDR3-VH refer to the three highly variable regions of the heavy chain variable region, and correspondingly, CDR1-VL, CDR2-VL and CDR3-VL refer to the three highly variable regions of the light chain variable region.

[0058] In this invention, A29L, A35R, and M1R are surface envelope proteins of monkeypox virus.

[0059] In a first aspect, the present invention provides a monkeypox virus binding protein selected from protein a, protein b, protein c, protein d, protein e, or protein f;

[0060] The protein a includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, as shown in SEQ ID NO.1-3, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, as shown in SEQ ID NO.4-6.

[0061] The protein b includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, with amino acid sequences as shown in SEQ ID NO.7-9, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, with amino acid sequences as shown in SEQ ID NO.10-12.

[0062] The protein c includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, with amino acid sequences as shown in SEQ ID NO.13-15, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, with amino acid sequences as shown in SEQ ID NO.16-18.

[0063] The protein d includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, with amino acid sequences as shown in SEQ ID NO.19-21, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, with amino acid sequences as shown in SEQ ID NO.22-24.

[0064] The protein e includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, as shown in SEQ ID NO. 25-27, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, as shown in SEQ ID NO. 28-30.

[0065] The protein f includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, with amino acid sequences as shown in SEQ ID NO. 31-33, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, with amino acid sequences as shown in SEQ ID NO. 34-36.

[0066] The amino acid sequences shown in SEQ ID NO.1 to 36 are shown in Table 1.

[0067] Table 1

[0068]

[0069]

[0070] The monkeypox virus binding protein provided by this invention has good specificity, high biological activity, strong stability, and high affinity for monkeypox virus, and can be used to prepare products for detecting monkeypox virus.

[0071] In some preferred embodiments, protein a includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO. 37-38, respectively.

[0072] The protein b includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO.39-40, respectively.

[0073] The protein c includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO.41-42;

[0074] The protein d includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO.43-44;

[0075] The protein e includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO.45-46, respectively.

[0076] The protein f includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO.47-48;

[0077] Preferably, the monkeypox virus binding protein is of rabbit origin.

[0078] The amino acid sequences shown in SEQ ID NO.37~48 are shown in Table 1.

[0079] Table 2

[0080]

[0081]

[0082]

[0083] Secondly, the present invention provides the application of the monkeypox virus binding protein in the preparation of monkeypox virus detection products.

[0084] Thirdly, the present invention provides a monkeypox virus detection test strip, the test strip comprising a base plate and a sample loading pad, a marking pad, a detection pad and a sample absorption pad sequentially stacked on the base plate;

[0085] The labeling pad contains the monkeypox virus binding protein, which is labeled with a marker that can be detected to identify the location or concentration of the marker.

[0086] The monkeypox virus test strip provided by this invention has the advantages of simple operation, rapid response, high sensitivity, strong specificity, suitability for rapid on-site detection, and cost-effectiveness. It can be used for rapid screening during a viral pandemic, and can quickly, accurately, and safely detect a large number of people, including suspected cases, asymptomatic infected cases in the incubation period, and asymptomatic virus carriers at higher risk. It indirectly aims to solve the problem of insufficient monkeypox nucleic acid detection capacity and reduce potential transmission risks.

[0087] In some preferred embodiments, the markers include, but are not limited to, at least one of colloidal gold, colored microspheres, time-resolved fluorescent microspheres, or quantum dot microspheres;

[0088] Preferably, the particle size of colloidal gold can be, for example, but not limited to, 40nm, 60nm, 80nm or 100nm;

[0089] Preferably, the particle size of the colored microspheres, time-resolved fluorescent microspheres, and quantum dot microspheres can be, for example, but not limited to, 100 nm, 150 nm, 200 nm, 250 nm, or 300 nm.

[0090] Preferably, the mass ratio of monkeypox virus conjugate protein coupled to colloidal gold is (0.04-0.32):1; the mass ratio of monkeypox virus conjugate protein to colored microspheres, time-resolved fluorescent microspheres or quantum dot microspheres is (0.1-0.4):1.

[0091] By adjusting the size and amount of marker particles, the sensitivity of the test strips can be improved.

[0092] In some preferred embodiments, the detection pad is provided with a detection line (T line) and a quality control line (C line);

[0093] The detection line is coated with 1–2 mg / ml of the monkeypox virus binding protein described above;

[0094] The quality control line is coated with 1–2 mg / ml of sheep-derived IgG polyclonal antibody;

[0095] Preferably, the diluent for monkeypox virus binding protein and sheep-derived IgG polyclonal antibody is a 15-25 mM PB buffer containing trehalose, with each 100 ml of diluent containing 0.1-0.9 g of trehalose.

[0096] In some preferred embodiments, the monkeypox virus binding protein on the labeled pad is different from the monkeypox virus binding protein on the detection pad.

[0097] For example, the protein on the labeling pad is monkeypox-binding protein a, c, or e, where a is monkeypox virus A29L monoclonal antibody 1, c is monkeypox virus A35R monoclonal antibody 1, and e is monkeypox virus M1R monoclonal antibody 1. The protein on the test pad is monkeypox-binding protein b, d, or f, where b is monkeypox virus A29L monoclonal antibody 2, d is monkeypox virus A35R monoclonal antibody 2, and f is monkeypox virus M1R monoclonal antibody 2.

[0098] The test strip provided by this invention is based on the principle of antigen-antibody reaction. It utilizes colloidal gold, colored microspheres, time-resolved fluorescent microspheres, and quantum dots to label monkeypox virus monoclonal antibodies, which are then immobilized on a glass fiber membrane. Another monoclonal antibody against monkeypox virus is coated onto the detection pad (e.g., NC membrane). Based on the principle of antigen-antibody reaction, detection can be performed visually or using a compatible instrument within the detection time. If monkeypox virus is present in the sample, a double-antibody sandwich structure is formed, resulting in a visible band or a light intensity signal on the instrument. If monkeypox virus is absent in the sample, no band appears on the NC membrane or no light intensity signal is detected on the instrument. The presence or absence of the signal allows for a negative / positive result determination, or the intensity of the light signal allows for a prediction of viral load.

[0099] Using the test strips provided by this invention, the entire process can yield test results in 15-20 minutes, which is fast and efficient. This helps medical personnel obtain test results in a timely manner, make comprehensive judgments based on the results, and take timely actions to avoid panic and reduce the spread of the epidemic.

[0100] Fourthly, the present invention provides a monkeypox virus detection kit, comprising the monkeypox virus detection test strip and a housing, wherein the monkeypox virus detection test strip is disposed inside the housing.

[0101] The monkeypox virus detection kit provided by this invention contains monkeypox virus detection test strips, and therefore has all the beneficial effects of monkeypox virus detection test strips.

[0102] In some preferred embodiments, the housing includes a detachably connected upper cover and a lower cover;

[0103] The top cover is equipped with an observation window and a sample application hole.

[0104] In this invention, there are no specific restrictions on the shape of the observation window and the sample application hole. The observation window can be square, for example, located above the test line and the control line of the test strip, and is used to observe the test results. The sample application hole can be a circular hole with a diameter of 0.5-1cm, located above the sample pad.

[0105] In some preferred embodiments, the test samples for the monkeypox virus detection kit include, but are not limited to, blood, saliva, pus from infected sites, or scabs; the samples can be collected in test tubes or can be samples attached to swabs.

[0106] Preferably, the monkeypox virus detection kit further includes a sample extraction solution, which can process samples such as saliva, blood, vesicles and pustules from infected skin tissue sites, and then be detected using the monkeypox virus detection kit of the present invention.

[0107] The blood sample extraction solution was prepared using 45–55 mM PB buffer, with each 100 mL of PB buffer containing: 0.4–0.6 g Tritonx-100, 0.1–0.3 g Proclin 300, 0.4–0.6 g sodium caseinate, and 0.8–1 g NaCl;

[0108] Extraction solutions for saliva samples and pustules from infected sites were prepared using 90–110 μM Tris buffer, with each 100 mL Tris buffer containing 0.9 g NaCl, 0.4–0.6 g Tritonx-100, and 0.4–0.6 g Tween 20, and the pH of the extraction solution was 8.5.

[0109] Taking serum samples as an example, the serum sample diluent and addition method are as follows:

[0110] Preparation of diluent:

[0111] For example, prepare a diluent for a blood sample in a 100ml volume for the monkeypox virus antigen detection kit:

[0112] (1) Weigh 1.79g Na2HPO4, 0.78g NaH2PO4, 0.5g sodium caseinate, and 0.9g NaCl using a balance, and dissolve them in water;

[0113] (2) Weigh 0.5g Tritonx-100 and 0.1g Proclin300 into an EP tube, and repeatedly wash the EP tube with the solution from step 1 until it is completely dissolved in water;

[0114] (3) Adjust the pH value to 8.0 with 4M NaOH or HCl, then add water to 100ml, and make up to volume with a 100ml volumetric flask;

[0115] Reagent kit sample loading:

[0116] (1) When testing blood samples (including plasma, serum, or whole blood) Figure 1After adding 1 drop of low-priced sample (approximately 40-50 μL) to the sample well, quickly add 1 drop (approximately 40-50 μL) of the prepared blood sample diluent to initiate the reaction;

[0117] (2) After 15 minutes, the results were analyzed according to different methodologies.

[0118] Taking saliva, vesicle, and pustular swab samples as examples, the extraction solutions and sample addition methods for saliva, vesicle, and pustular swabs are as follows:

[0119] Preparation of the extract:

[0120] Prepare the swab extract for the monkeypox virus antigen detection kit using 100ml as an example:

[0121] (1) Weigh 12.1g of Ttis and 8.7g of NaCl and dissolve them in 80ml of water;

[0122] (2) Weigh 0.5g Tritonx-100 and 0.5g Tween 20 into an EP tube, and repeatedly wash the EP tube with the solution from step 1 until it is completely dissolved in water;

[0123] (3) Adjust the pH value to 8.5 with 4M NaOH or HCl, then add water to 100ml, and make up to volume with a 100ml volumetric flask;

[0124] Processing and loading of saliva, vesicle, and pustular swab samples:

[0125] (1) Samples were collected from saliva, vesicles and pustules using swabs.

[0126] (2) Immerse the sampled swab in the extraction tube and stir for 6-8 times, or immerse the sampled swab in the extraction solution for 1 minute;

[0127] (3) After capping the extraction tube, add 2-3 drops of the extraction sample mixture (about 100ul) into the sample well;

[0128] (4) After 15 minutes, the test results are analyzed according to different methodologies.

[0129] The above-mentioned extract solution showed good detection results for the corresponding samples.

[0130] The present invention will be further illustrated below with specific embodiments and comparative examples. However, it should be understood that these embodiments are merely for the purpose of more detailed illustration and should not be construed as limiting the present invention in any way.

[0131] It should be noted that, unless otherwise specified, in the following examples, the diluent for monkeypox virus binding protein and goat anti-rabbit IgG polyclonal antibody is 20mM PB buffer containing trehalose, and each 100ml of diluent contains 0.5g of trehalose.

[0132] The blood sample extraction solution was prepared using 50mM PB buffer, with each 100mL of PB buffer containing: 0.5g Tritonx-100, 0.2g Proclin300, 0.5g sodium caseinate, and 0.9g NaCl;

[0133] Extraction solutions for saliva samples and pustules from infected sites were prepared using 100 mL Tris buffer, each 100 mL of which contained 0.9 g NaCl, 0.5 g Tritonx-100, and 0.5 g Tween 20, with a pH of 8.5.

[0134] Example 1

[0135] The monkeypox virus binding proteins include: monkeypox virus A29L monoclonal antibody 1, monkeypox virus A29L monoclonal antibody 2, monkeypox virus A35R monoclonal antibody 1, monkeypox virus A35R monoclonal antibody 2, monkeypox virus M1R monoclonal antibody 1, and monkeypox virus M1R monoclonal antibody 2. The variable region sequences of the above binding proteins are shown in Table 2.

[0136] A 12% SDS-PAGE gel was prepared using standard methods. The antibodies were loaded at 5 μg values, and electrophoresis was performed using protein molecular weight standards as a reference. The results showed that the six anti-monkeypox virus monoclonal antibodies exhibited two characteristic bands of approximately 25 KD and 55 KD, representing the light and heavy chains of IgG, respectively. Figure 4 The antibody content of all bands was above 90% after scanning and analysis.

[0137] Figure 4Among them, 1: Anti-MPXV-A29L-1; 2: Anti-MPXV-A29L-2; 3: Anti-MPXV-A35R-1; 4: Anti-MPXV-A35R-2; 5: Anti-MPXV-M1R-1; 6: Anti-MPXV-M1R-2. Among them, Anti-MPXV-A29L-1 is anti-monoclonal antibody 1 against monkeypox virus A29L; Anti-MPXV-A29L-2 is anti-monoclonal antibody 2 against monkeypox virus A29L; Anti-MPXV-A35R-1 is anti-monoclonal antibody 1 against monkeypox virus A35R; Anti-MPXV-A35R-2 is anti-monoclonal antibody 2 against monkeypox virus A35R; Anti-MPXV-M1R-1 is anti-monoclonal antibody 1 against monkeypox virus M1R; and Anti-MPXV-M1R-2 is anti-monoclonal antibody 2 against monkeypox virus M1R.

[0138] The antibodies used in the following examples are the same as those in Example 1.

[0139] Example 2

[0140] A monkeypox virus detection kit, such as Figures 1-3 As shown, the device includes a monkeypox virus test strip and a housing, with the test strip disposed inside the housing. The monkeypox virus test strip includes a base plate 4 and, sequentially stacked on the base plate, a sample loading pad 8, a marking pad 7, a detection pad 5, and a sample absorption pad 6; the detection pad has a detection line 10 and a control line 9; the housing includes a detachably connected upper cover and a lower cover; the upper cover has an observation window 1 and a sample application hole 2, and the lower cover has a test strip loading area 3.

[0141] Example 3: Preparation of monkeypox antigen detection kit using colloidal gold-labeled antibodies

[0142] 1. Main Materials

[0143] 1.1 Antibodies: Rabbit anti-A29L, A35R, and M1R monoclonal antibodies are all self-developed antibodies of our company, which are rabbit-derived monoclonal antibodies, and are labeled and coated respectively; Goat anti-rabbit IgG antibody: a product of Shenzhen Feipeng Biotechnology Co., Ltd., used for coating nitrocellulose membrane quality control lines respectively.

[0144] 1.2 Nitrocellulose membrane: NC membrane is a Sartorius product.

[0145] 1.3 Other consumables: PVC boards and other consumables are products of Bikenlab; commonly used reagents are all analytical grade reagents.

[0146] 1.4 Acquisition of recombinant antigens: Based on data on monkeypox virus published in the NCBI database, recombinant antigens of A29L, A35R, and M1R proteins were commercially synthesized by Sangon Biotech (Shanghai) Co., Ltd.

[0147] 2 methods

[0148] 2.1 Preparation of colloidal gold labeling pads:

[0149] The preparation steps of the colloidal gold labeling pad are as follows:

[0150] (1) Take 1 ml of colloidal gold solution with a particle size of 40 nm and adjust the pH value to 8.5 with 0.2 M K2CO3;

[0151] (2) Add 25ug of A29L monoclonal antibody 1 (or A35R monoclonal antibody 1 or M1R monoclonal antibody 1). The mass ratio of antibody to colloidal gold particles is 0.1:1. Adjust the rotating shaker to a certain speed, rotate and label at room temperature for 1.5h, and then add 20ul of blocking solution.

[0152] (3) Centrifuge at 12000 rpm for 15 min and discard the supernatant;

[0153] (4) Add 100 μL of colloidal gold complex solution;

[0154] (5) The above concentrate is diluted at a ratio of 1:7, sprayed with gold, and then placed in a drying oven at 37°C for 2 hours for later use.

[0155] 2.2NC membrane coating:

[0156] A29L monoclonal antibody 2 (if the above colloidal gold-labeled antibody is A35R monoclonal antibody 1, then A35R monoclonal antibody 2 is used here; if the above colloidal gold-labeled antibody is M1R monoclonal antibody 1, then M1R monoclonal antibody 2 is used here) was diluted to 1.5 mg / ml and goat anti-rabbit IgG was diluted to 2 mg / ml using 0.02 M PB containing 0.5% trehalose. Then, the detection line T and control line C were respectively streaked on the nitrocellulose membrane using a membrane sprayer. After coating, the NC membrane was dried in an oven at 37°C for 24 hours for later use.

[0157] 2.3 Assembly of the reagent kit:

[0158] In a drying chamber, the coated nitrocellulose membrane is placed in the middle of a plastic support plate and adhered. The marker colloidal gold pad is overlapped (1 / 3 of the colloidal gold pad) on one side of the nitrocellulose membrane along the T-line, and the sample pad is overlapped (1 / 5 of the colloidal gold pad) on the other side. The absorption pad is overlapped (1 / 10 of the absorption pad) on one side of the nitrocellulose membrane along the C-line. The plastic plate is then cut into strips of a specific width using a cutting machine, and these strips are inserted into the test card to form a monkeypox virus antigen detection kit.

[0159] 2.4 Testing:

[0160] Step 1: Remove the reagent kit and sample to be tested, and allow them to equilibrate to room temperature. Step 2: Open the sealed aluminum foil bag, remove the reagent kit, and place it flat on the table. Step 3: Use a pipette to add 50 μL of serum to the sample well, then quickly add 50 μL of sample diluent, or insert the sampling swab into the extraction tube and stir repeatedly 6-7 times before removing the swab. Tightly cap the extraction tube and add 3 drops of sample. Step 4: Set a timer and read the results after 15 minutes. Note: If the sample does not undergo lateral chromatography or filtration within 1 minute after adding the sample, it may be due to excessive viscosity, requiring pretreatment with physiological saline.

[0161] 3 Results

[0162] Under lateral chromatography, when monkeypox virus is present in the sample, the test line will show color, and the control line will also show color. Figure 5 (a) When there is no monkeypox virus in the sample, the test line does not show color, while the control line shows color. Figure 5 (b) After sample loading, if the control line does not develop color, the result is considered invalid regardless of whether the detection line develops color. Figure 5 c in Figure 5 (d)

[0163] Example 4: Preparation of a monkeypox virus antigen detection kit using time-resolved fluorescent microsphere-labeled antibodies.

[0164] A monkeypox virus antigen detection kit was prepared using three pairs of monkeypox virus monoclonal antibodies independently developed and prepared by our company. The kit includes a test card and a test strip. The test card consists of a top cover and a bottom cover. The test strip is embedded in a fluorescent pad with time-resolved fluorescent microspheres labeled A29L monoclonal antibody 1 (or A35R monoclonal antibody 1 or M1R monoclonal antibody 1). The test line is coated with A29L monoclonal antibody 2 (or A35R monoclonal antibody 2 or M1R monoclonal antibody 2). The monkeypox virus antigen in the sample is quantitatively detected using the double antibody sandwich method.

[0165] 1. Reagent kit preparation procedure:

[0166] The time-resolved fluorescent microspheres were labeled with A29L monoclonal antibody 1 (or A35R monoclonal antibody 1 or M1R monoclonal antibody 1) prepared using the method of this invention. Specific examples are as follows:

[0167] Time-resolved fluorescent microsphere antibody labeling: Add 9 mL of MES buffer to 1 mL of 1% carboxyl time-resolved fluorescent microspheres, then add 25 μL of EDC solution (10 mg / mL) and 25 μL of NHS solution (10 mg / mL). Incubate at room temperature with shaking for 30 min, then centrifuge to collect the precipitate. Add HEPES reconstitution solution, sonicate to disperse evenly, then add 1 mL of 1 mg / mL A29L monoclonal antibody 1 (or A35R monoclonal antibody 1 or M1R monoclonal antibody 1). Incubate at room temperature with shaking for 120 min, then centrifuge to collect the precipitate. Add 1 mL of blocking buffer, incubate at room temperature with shaking for 120 min. Centrifuge to collect the microsphere precipitate and reconstitute with the reconstitution solution.

[0168] Preparation of fluorescent pads: The labeled time-resolved fluorescent microspheres were diluted with a microsphere reconstitution solution and coated onto the fluorescent pads using a gold spraying apparatus at a spraying density of 3 μL / cm and a spraying spacing of 6 mm. After coating, the pads were dried at 37°C and low humidity (<30%) for 2 hours.

[0169] NC membrane coating of CT lines: T lines were coated with A29L monoclonal antibody 2 at a concentration of 1.5 mg / mL (if the above colloidal gold-labeled antibody is A35R monoclonal antibody 1, then A35R monoclonal antibody 2 is selected here; if the above colloidal gold-labeled antibody is M1R monoclonal antibody 1, then M1R monoclonal antibody 2 is selected here), and C lines were coated with goat anti-rabbit IgG antibody at a concentration of 1 mg / mL, 1 μL / cm. After the procedure, the lines were dried at 37℃ and low humidity (<30%) for 24 h.

[0170] Sample pad preparation: The sample pad preparation solution consists of buffer salts, slow-release agents, solubilizers, and blocking agents. The specific formulation is 20mM Tris buffer, with each 100mL of Tris buffer containing 1g BSA, 0.5g Tween 20, and 2g sucrose. Apply according to a 20cm... 2 Use 1 mL of sample processing solution for treatment. After thorough treatment, place the sample in a 37°C, low humidity (<30%) environment for 2 hours to dry.

[0171] Test strip assembly: Attach the NC film, sample absorption pad, fluorescent pad, and sample loading pad sequentially to a PVC board. The sample absorption pad and fluorescent pad should each overlap the NC film by 1-2 mm, and the sample loading pad should overlap the fluorescent pad by 1-2 mm. After assembly, cut the test strip to a width of 4±0.4 mm and insert it into a cartridge. Place the cartridge and desiccant together in an aluminum foil bag and seal it. Affix labels and box to obtain the finished test card.

[0172] Test sample preparation: Recombinant antigens of A29L, A35R, and M1R proteins, commercially synthesized by Sangon Biotech (Shanghai) Co., Ltd., were serially diluted before testing.

[0173] 2. Kit Detection Process

[0174] Place the test card on a clean, flat surface, and add 90–100 μL of the processed sample to the sample dispensing end of the test card. At the same time, set up a PBS control group.

[0175] Import the standard curve of the test strip. After 15 minutes, use a fluorescence immunoassay analyzer to scan the detection area to obtain the fluorescence signal. The concentration value corresponding to the monkeypox virus antigen will be displayed after the detection. The measurement results are shown in Tables 3 and 4 below.

[0176] Table 3. Test results of diluent samples

[0177]

[0178] Table 4 Results of Positive Recombinant Antigen Tests

[0179]

[0180] Example 5: Preparation of Monkeypox Virus Antigen Detection Kit Using Colored Microsphere Labeled Antibodies

[0181] Monkeypox virus antigen test strips are prepared using three pairs of monkeypox virus monoclonal antibodies independently developed by our company. The test strips have A29L monoclonal antibody 1 (or A35R monoclonal antibody 1 or M1R monoclonal antibody 1) labeled with colored microspheres embedded in the label pad, and the detection line is coated with A29L monoclonal antibody 2 (or A35R monoclonal antibody 2 or M1R monoclonal antibody 2). The double antibody sandwich method is used to qualitatively detect monkeypox virus antigen in the sample.

[0182] 1. Preparation of test strips:

[0183] 1.1 Colored microsphere labeled antibody

[0184] (1) The pH of the 100 nm colored microspheres was adjusted to 8.0 using 0.1 mol / L K2CO3;

[0185] (2) Take 1 mL of the pH-adjusted solution above and add 30 μg of A29L monoclonal antibody 1 (or A35R monoclonal antibody 1 or M1R monoclonal antibody 1). The mass ratio of antibody to colored microspheres is 0.3:1. After reacting at room temperature for 1 h, centrifuge and discard the supernatant. Take 1 mL of the pH-adjusted solution above and add 5 μg of chicken IgY. The mass ratio of antibody to colored microspheres is 0.05:1. After reacting at room temperature for 1 h, centrifuge and discard the supernatant.

[0186] (3) Add 1 mL of 20% BSA and block for 2 h, then centrifuge and discard the supernatant;

[0187] (4) After reconstitute the above microspheres with 100uL of pH 8.0 reconstituted solution, the two types of microspheres were mixed at a ratio of 5:1, and the mixture was diluted with reconstituted solution at a ratio of 15%.

[0188] 1.2 Preparation of Marking Pads

[0189] The diluted solution of the labeled colored microsphere antibody complex was sprayed onto the labeling pad using a gold spray patterner at a rate of 7.5 μL / cm and a spraying spacing of 6 mm. After spraying, the pad was dried at 37°C with low humidity (<30%) for 2 hours.

[0190] 1.3 Preparation of the sample pad

[0191] The sample loading pad treatment solution consists of buffer salts, slow-release agents, solubilizers, and blocking agents. The specific formulation is 20 mM Tris, 1% BSA, 0.5% Tween 20, and 2% sucrose. Use 1 mL of sample treatment solution per 20 cm². After homogenization, dry at 37°C with low humidity (<30%) for 2 hours.

[0192] 1.4C / T wire wrapping

[0193] The T line was streaked with 1.5 mg / mL A29L monoclonal antibody 2 (if the colloidal gold-labeled antibody is A35R monoclonal antibody 1, then 1.2 mg / mL A35R monoclonal antibody 2 is used here; if the colloidal gold-labeled antibody is M1R monoclonal antibody 1, then 2.1 mg / mL M1R monoclonal antibody 2 is used here). The C line was streaked with 2 mg / mL goat anti-chicken IgY antibody at 1 μL / cm. After the streaking, the line was dried at 37°C with low humidity (<30%) for 24 hours.

[0194] 1.5 Test strip assembly

[0195] The sample absorption pad, NC membrane, and labeling pad are sequentially attached to the PVC board. The sample absorption pad and labeling pad are each pressed against the NC membrane by 1-2 mm, and the sample loading pad is pressed against the labeling pad by 1-2 mm. After assembly, the test strips are cut to a width of 4±0.4 mm and placed in the cartridge. The cartridge and desiccant are placed together in an aluminum foil bag. Labeling and boxing completes the finished reagent kit.

[0196] 1.6 Sample preparation: Recombinant antigens of A29L, A35R, and M1R proteins, commercially synthesized by Sangon Biotech (Shanghai) Co., Ltd., were serially diluted for testing.

[0197] 2 tests

[0198] Place the test strip on a clean, flat surface. Add 90–100 μL of the prepared recombinant antigen sample to the sample application end of the test strip, and include a PBS control group. After 10 minutes, observe the test strip window. Two lines in the window should be positive, and only one line (C) should be negative. The results are as follows: The results show that the antigen concordance rate of the test strips assembled from the three pairs of monoclonal antibodies is 100%.

[0199] Table 5

[0200]

[0201]

[0202] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A pair of monkeypox virus binding proteins characterized in that, It is composed of monkeypox virus binding protein c and monkeypox virus binding protein d; the monkeypox virus binding protein c and monkeypox virus binding protein d are monoclonal antibodies against monkeypox virus A35R; The monkeypox virus binding protein c includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, as shown in SEQ ID NO. 13-15, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, as shown in SEQ ID NO. 16-18. The monkeypox virus binding protein d includes heavy chain complementarity-determining regions CDR1-VH, CDR2-VH, and CDR3-VH, as shown in SEQ ID NO. 19-21, and light chain complementarity-determining regions CDR1-VL, CDR2-VL, and CDR3-VL, as shown in SEQ ID NO. 22-24.

2. The monkeypox virus binding protein pair according to claim 1, characterized in that, The monkeypox virus binding protein c includes a heavy chain variable region and a light chain variable region with amino acid sequences as shown in SEQ ID NO.41~42. The monkeypox virus binding protein d includes a heavy chain variable region and a light chain variable region, with amino acid sequences as shown in SEQ ID NO.43~44.

3. The monkeypox virus binding protein pair according to claim 1, characterized in that, The monkeypox virus binding protein c and monkeypox virus binding protein d are of rabbit origin.

4. The use of the monkeypox virus binding protein pair according to any one of claims 1 to 3 in the preparation of monkeypox virus detection products.

5. A monkeypox virus detection test strip, characterized in that, The test strip includes a base plate and a sample pad, a marking pad, a detection pad, and a sample absorption pad that are stacked on the base plate in sequence. The labeling pad contains one of the monkeypox virus binding proteins according to any one of claims 1 to 3, and the monkeypox virus binding protein is labeled with a marker. The test pad is equipped with test lines and quality control lines; The detection line is coated with one of the monkeypox virus binding proteins as described in any one of claims 1 to 3, at a concentration of 1 to 2 mg / ml; The quality control line is coated with 1-2 mg / ml of sheep-derived IgG polyclonal antibody; The monkeypox virus binding protein on the labeling pad is different from the monkeypox virus binding protein on the detection pad.

6. The monkeypox virus detection test strip according to claim 5, characterized in that, The marker includes at least one of colloidal gold, colored microspheres, time-resolved fluorescent microspheres, or quantum dot microspheres.

7. The monkeypox virus detection test strip according to claim 6, characterized in that, The particle size of colloidal gold is 40~100nm; The particle sizes of colored microspheres, time-resolved fluorescent microspheres, and quantum dot microspheres are each 100-300 nm.

8. The monkeypox virus detection test strip according to claim 6, characterized in that, The mass ratio of monkeypox virus binding protein to colloidal gold was (0.04~0.32):1; the mass ratio of monkeypox virus binding protein to colored microspheres, time-resolved fluorescent microspheres, or quantum dot microspheres was (0.1~0.4):

1.

9. The monkeypox virus detection test strip according to claim 5, characterized in that, The diluent for monkeypox virus binding protein and sheep-derived IgG polyclonal antibodies was a 15-25 mM PB buffer containing trehalose, with each 100 ml of diluent containing 0.1-0.9 g of trehalose.

10. A monkeypox virus detection kit, characterized in that, The invention includes the monkeypox virus test strip and housing as described in any one of claims 5 to 9, wherein the monkeypox virus test strip is disposed inside the housing.

11. The monkeypox virus detection kit according to claim 10, characterized in that, The housing includes a detachably connected upper cover and a lower cover; The top cover is equipped with an observation window and a sample application hole.

12. The monkeypox virus detection kit according to claim 10, characterized in that, The test samples for the monkeypox virus detection kit are selected from pustules or scabs at the site of infection.

13. The monkeypox virus detection kit according to claim 12, characterized in that, The monkeypox virus detection kit also includes a sample extraction solution; The extraction solution for the pustular fluid samples from the infected site was 90-110 mM Tris buffer. Each 100 mL of 90-110 mM Tris buffer contained 0.9 g NaCl, 0.4 g-0.6 g Triton X-100, and 0.4 g-0.6 g Tween 20. The pH of the extraction solution was 8.5.

Citation Information

Patent Citations

  • Detection kit for monkey pox virus antigen and preparation method thereof

    CN114755418A

  • Compositions and methods for diagnosis and treatment of orthopoxviruses

    US20100316653A1